Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
With an annual R&D budget of about $11-12 billion—representing roughly a high-teens percentage of revenue—the company plans to allocate resources to key areas such as Oncology and reaffirmed its commitment to programs targeting obesity, cardiovascular, and metabolic diseases.Goldman Sachs hosted a meeting with Pfizer Inc's (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025).
高盛與輝瑞公司（紐交所：PFE）新任首席科學官克里斯·博紹夫（自2025年1月1日起生效）舉行了會議。
The analyst maintains the Buy rating with a price target of $33.
分析師維持買入評級，目標價格爲33美元。
When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk and low-risk projects.
在討論輝瑞的核心能力時，評論強調了戰略轉型，優先考慮投入的努力。焦點將放在預計能夠提供最高經濟回報的機會，同時保持高風險和低風險項目的平衡組合。
With an annual R&D budget of about $11-12 billion—representing roughly a high-teens percentage of revenue—the company plans to allocate resources to key areas such as Oncology and reaffirmed its commitment to programs targeting obesity, cardiovascular, and metabolic diseases.
公司擁有約110-120億的年度研發預算——佔營業收入的高單位百分比——計劃將資源分配到腫瘤學等關鍵領域，並重申其對針對肥胖、心血管和代謝疾病項目的承諾。
The analyst notes that Boshoff believes the anti-obesity medicine market is still in its early stages. He envisions a future in which the market is segmented based on factors like co-morbidities, different treatment mechanisms, delivery methods (Pfizer focuses on oral delivery), and combination therapies playing crucial roles.
分析師指出，博紹夫認爲抗肥胖藥物市場仍處於早期階段。他設想未來市場將根據合併症、不同治療機制、交付方式（輝瑞專注於口服制劑）以及組合療法在關鍵角色上進行細分。
Boshoff told the analyst that anti-obesity medicines are expected to become more integrated into primary care. He highlighted Pfizer's strong history with widely used medications like Lipitor and Eliquis, suggesting this experience aligns with their strategic goals.
博紹夫告訴分析師，抗肥胖藥物預計將更好地融合入初級護理中。他強調輝瑞在廣泛使用的藥物如立普妥和艾力克斯方面具有良好的歷史，暗示這一經驗與他們的戰略目標一致。
Among Pfizer's three clinical-stage anti-obesity programs, Boshoff expressed confidence in one molecule potentially being among the first oral GLP-1/AOMs available in the U.S. market.
在輝瑞的三項臨床階段抗肥胖項目中，博紹夫表達了對一種分子有潛力成爲美國市場首批口服GLP-1/AOM的信心。
Goldman Sachs adds that Pfizer sees Comirnaty and Paxlovid as reliable long-term products. The company expects steady demand due to ongoing COVID-19 mutations. The company anticipates more stable vaccination rates and improved commercial stability overall.
高盛補充稱，輝瑞將Comirnaty和Paxlovid視爲可靠的開多產品。由於持續的COVID-19變異，該公司預計將有穩定的需求。整體而言，該公司預期疫苗接種率將更穩定，商業穩定性將得到改善。
In the third quarter, the U.S. drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion.
在第三季度，這家美國製藥公司報告銷售額達到177億美金，同比增長31%（運營增長32%），超出了149.5億美金的預期。
The increase was primarily led by growth contributions from Paxlovid and several acquired products, key in-line products, and recent commercial launches.
主要增長貢獻來自Paxlovid和幾種收購產品、關鍵在售產品以及最近的商業推出。
Regarding its COVID-19 and influenza combination vaccine, Pfizer remains optimistic about its market potential and is testing new formulations to overcome challenges from earlier clinical data.
關於其COVID-19和流感組合生物-疫苗，輝瑞對其市場潛力依然持樂觀態度，並正在測試新配方以克服早期臨床數據顯示的挑戰。
Pfizer recognizes setbacks in its immunology pipeline but remains committed and plans to focus on advancing select early-stage pipeline projects.
輝瑞承認其免疫學管線遭遇挫折，但仍然保持承諾，並計劃專注於推進選定的早期階段管線項目。
Price Action: PFE stock is down 0.77% at $25.62 at last check Tuesday.
價格動態：截至週二最後一次檢查時，PFE股票下跌0.77%，報25.62美金。
譯文內容由第三人軟體翻譯。